| Price | 61.50p on 09-01-2026 at 19:40:05 |
|---|---|
| Change | -0.50p -0.81% |
| Buy | 62.00p |
| Sell | 61.00p |
| Last Trade: | Unknown 20,000.00 at 61.50p |
| Day's Volume: | 1,017,432 |
| Last Close: | 61.50p |
| Open: | 62.00p |
| ISIN: | GB00BYYW9G87 |
| Day's Range | 61.00p - 62.00p |
| 52wk Range: | 27.25p - 83.20p |
| Market Capitalisation: | £266.70m |
| VWAP: | 61.65953p |
| Shares in Issue: | 433.66m |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Avacta Group (AVCT) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 20,000 | 61.50p | OTC Trade |
17:06:46 - 09-Jan-26 |
| Buy* | 5,000 | 61.6969p | Ordinary |
16:29:55 - 09-Jan-26 |
| Buy* | 290 | 62.00p | Ordinary |
16:28:59 - 09-Jan-26 |
| Buy* | 50,000 | 62.00p | Ordinary |
16:26:00 - 09-Jan-26 |
| Buy* | 100,000 | 62.00p | Ordinary |
16:24:29 - 09-Jan-26 |
| Buy* | 1,000 | 61.70p | Ordinary |
16:19:37 - 09-Jan-26 |
| Buy* | 60,000 | 61.75p | Ordinary |
16:14:47 - 09-Jan-26 |
| Sell* | 3,237 | 61.00p | Ordinary |
16:12:13 - 09-Jan-26 |
| Sell* | 1,784 | 61.4219p | Ordinary |
16:11:46 - 09-Jan-26 |
| Sell* | 5,683 | 61.425p | Ordinary |
16:09:29 - 09-Jan-26 |
Avacta Group (AVCT) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 18th Dec 2025 7:00 am | RNS-R | Avacta reports new AVA6103 pharmacology data |
| 17th Dec 2025 7:00 am | RNS | Faridoxorubicin Phase 1b SGC data |
| 8th Dec 2025 7:00 am | RNS | Preliminary Data in Faridoxorubicin Phase 1b Trial |
| 3rd Nov 2025 8:24 am | RNS | Completion of Placing and TVR |
| 27th Oct 2025 5:39 pm | RNS | Block Listing Six Monthly Return |
| 27th Oct 2025 7:00 am | RNS | Avacta presents preclinical data at AACR-NCI-EORTC |
| 23rd Oct 2025 5:00 pm | RNS-R | Notice of Investor Presentation |
| 20th Oct 2025 7:01 am | RNS | Equity fundraise of £16 million |
| 20th Oct 2025 7:00 am | RNS | Avacta Presents Phase 1a Data for Faridoxorubicin |
| 13th Oct 2025 7:00 am | RNS | Avacta to present data at EORTC-NCI-AACR |
